Humalog(insulin lispro)
Admelog, Humalog, Liprolog, Liumjev, Lyumjev (insulin lispro) is a protein pharmaceutical. Insulin lispro was first approved as Humalog on 1996-04-30. It is used to treat hyperglycemia, type 1 diabetes mellitus, and type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Admelog, Humalog, Lyumjev
CombinationsHumalog mix
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin lispro
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Humalog | insulin lispro | Eli Lilly | N-20563 RX | 1996-06-14 | 5 products |
| Humalog | insulin lispro | Eli Lilly | N-205747 RX | 2015-05-26 | 1 products |
| Lyumjev | insulin lispro-aabc | Eli Lilly | N-761109 RX | 2020-06-15 | 6 products |
| Admelog | insulin lispro | Sanofi | N-209196 RX | 2017-12-11 | 3 products |
Show 1 discontinued
Insulin lispro
+
Insulin lispro protamine
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| admelog | Biologic Licensing Application | 2020-11-30 |
| humalog | Biologic Licensing Application | 2023-05-15 |
| lyumjev lyumjev | Biologic Licensing Application | 2020-06-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperglycemia | HP_0003074 | D006943 | R73.9 |
| type 1 diabetes mellitus | EFO_0001359 | D003922 | E10 |
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AB: Insulins and analogues for injection, fast-acting
— A10AB04: Insulin lispro
— A10AC: Insulins and analogues for injection, intermediate-acting
— A10AC04: Insulin lispro
— A10AD: Insulins and analogues for injection used in diabetes, intermediate- or long-acting combined with fast-acting
— A10AD04: Insulin lispro
HCPCS
No data
Clinical
Clinical Trials
253 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 46 | 22 | 25 | 16 | 18 | 122 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 13 | 5 | 22 | 32 | 4 | 75 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 6 | 7 | 5 | 3 | 4 | 23 |
| Healthy volunteers/patients | — | 16 | 1 | — | 1 | — | 18 | ||
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | 3 | 5 | — | 8 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | 1 | |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 | |
| Hospitalization | D006760 | — | — | — | 1 | — | 1 | ||
| Peritoneal dialysis | D010530 | — | — | — | 1 | — | 1 | ||
| Ventricular dysfunction | D018754 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | N18 | — | — | 1 | — | — | 1 | |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 1 | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 1 | 1 |
| Orthostatic hypotension | D007024 | I95.1 | — | — | — | — | 1 | 1 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | — | 1 | 1 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | INSULIN LISPRO |
| INN | insulin lispro |
| Description | Insulin lispro recombinant |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 5UDP, 6NWV |
| CAS-ID | 133107-64-9 |
| RxCUI | 86009 |
| ChEMBL ID | CHEMBL1201538 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00046 |
| UNII ID | GFX7QIS1II (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Humalog - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,254 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,464 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more